Savella

(milnacipran)

Fibromyalgia

MOA: inhibitor of serotonin/Norepinephrine uptake. Exact MOA of central pain inhibition is unknown

RiaSTAP

(fibrinogen concentrate)

Congenital fibrinogen deficiency

MOA: Physiological substrate of 3 enzymes: thrombin, factor XIIIa, and plasmin. End result = cross-linked fibrin --> clot is more resistant to fibrinolysis.

Agriflu

(influenza virus vaccine)

Immunization against subtypes A and B influenza virus

ATryn

(anthrombin alfa, recombinant)

Hereditary antithrombin deficiency

MOA: Recombinant antithrombin. Complexes with thrombin and Factor Xa (neutralizing their activity in the process of coagulation)

Uloric

(febuxostat)

Gout

MOA: xanthine oxidase inhibitor

Afinitor

(everlimus)

Renal cell carcinoma

MOA: Protein kinase inhibitor

Ixiaro

(Japanese encephalitis vaccine, inactivated)

Coartem

(artemether/lumefantrine)

Acute, uncomplicated malaria

MOA: Inhibit nucleic acid and protein synthesis of malaria

Ulesfia

(benzoyl alcohol lotion)

Simponi

(golimumab)

RA, psoriatic arthritis, and ankylosing spondylitis

MOA: Human monoclonal antibody that binds to soluble and transmembrane bioactive forms of TNFa

Dysport

(abobutulinumtoxinA)

Cervical dystonia, wrinkles

MOA: inhibits ACh release from peripheral cholinergic nerve endings resulting in localized reduction of muscle activity

Fanapt

(iloperidone)

Schizophrenia

MOA: unknown, proposed to be a D2 and 5HT2 receptor antagonist

Samsca

(tolvaptan)

Hypervolemic and euvolemic hyponatremia

MOA: V2 receptor antagonist which causes an increase in urine water excretion

Besivance

(besifloxacin topical conjuctivitis)

Bacterial conjuctivitis

MOA: inhibit DNA gyrase and topoisomerase IV

Ilaris

(canakinumab)

Cyropurin-associated periodic syndroms (CAPS)

MOA: Human Il-1b monoclonal antibody of the IgG1/kappy isotype. Blocks inflammation.

Multaq

(dronedarone)

A. fib, atrial flutter

MOA: Exact MOA is unkown. Antiarrhythmic effects similar to all 4 classes. Inhibits Ca++, Na+, and K+ channels, and is an alpha/beta recptor antagonist

Effient

(prasugrel)

Reduction of thrombotic CV events

MOA: Inhuibits platelet activation/aggregation via irreversible inhibition of P2Y12 adenospine diphosphate receptor (ADP).

Onglyza

(saxagliptin)

T2DM

MOA: DPP4 enzyme inhibitor

Livalo

(pitavastatin)

Hyperlipidemia

MOA: HMG-CoA reductase inhibitor

Saphris

(asenapine)

Schizophrenia, Bipolar I Disorder

MOA: Unknown; may be mediated through antagonist activity at D2 and 5HT2A receptors

Hiberix

(Haemophilis b conjugate vaccine)

Sabril

(vigabatrin)

Infantile spasms, partial complex seizures

MOA: Unknown; primarily result of action as irreversible inhibitor of GABA-T

Bepreve

(bepotastine opthalmic solution)

Alergic conjuctivitis

MOA: H1 receptor antagonist; inhibit release of histamine from mast cells

Vibativ

(telavancin)

Complicated skin/skin structure infections due to susceptible Gm + bacteria

MOA: lipoglycopeptide antibiotics which inhibits cell wall synthesis

Gammaplex

(immune globulin, human)

Primary humoral immunodeficiency

MOA: unknown; helps in inflammatory/autoimmune processes

Folotyn

(pralatrexate)

Peripheral T-Cell Lymphoma

MOA: Dihydrofolate reductase inhibitor

Stelara

(ustekinumab)

Plaque psoriasis

MOA: Human IgG1-kappa monoclonal antibody that binds to IL-12 and IL-13 cytokines which are involved in inlammatory/immune response

Acute attacks of herditary angioedema

MOA: C1 inhibitor. Also regulates the fibrinolytic pathway.

Cervarix

(HPV bivalent [type 16 and 18] vaccine, recombinant)

Votrient

(paxzopanib)

Advanced renal cell carcinoma

MOA: Tyrosine kinase inhibitor, inhibits EGFs as well

Arzerra

(ofatumumab)

Chronic lymphocytic leukemia

MOA: IgG1-kappa monclonal antibody that binds to CD20 molecule on normal B lymphocytes and on B-bell chronic lymphocytic leukemia cells, resulting in B-cell lysis

Istodax

(romidepsin)

Cutaneous T-Cell Lymphoma

MOA: Inhbitis histone deacetylase (HDAC), resuling in accumulation of acetylated histones. Induces cell cycle arrest and apoptosis of some cancer cells.

Kalbitor

(ecellantide)

Acute attacks of heriditary angioedema

MOA: Human plasma kallikrein inhibitor, which inhibits formation of bradykinin.

Wilate

(von Willebrand factor/coagulation factor VIII)

von Willebrand disease

MOA: Lyophillized concentrate of Factor VIII and von Willebrand Factor. Facilitates activation of Factor X and causes formation fo thrombin and fibrin promoting platelet aggregation and adhesion to damaged vascular endothelium)

Rapaflo

(silodosin)

BPH

MOA: Selective antagonist of alpha 1 adenoreceptors

Lastacaft

(alcaftadine)

Allergic conjuctivitis

MOA: H1 histamine receptor antagonist

Glassia

(Alpha-1 protease inhibitor)

Chronic augmentation and maintenance therapy in adults with emphysema due to congential deficiency of alpha-1 protease inhibitor

MOA: augments the level of deficient protein and theorteically corrects the imbalance between neutrophil elastase and protease inhibitors, which may protect the lower respiratory tract

Lumizyme

(alglucosiadase alpha)

(+ prednisone), treatment of late-onset Pompe disease in 8+ patients who do not have evidence of cardiac hypertrophy

MOA: Source of GAA. Binds to lysozymes and is internalized, resulting in increased enzymatic activity in cleaving glycogen

Jevtana

(cabazitaxel)

(+ prednisone), tx of androgen-independent prostate cancer in men who have already received docetaxel

MOA: Stabilized microtubules to inhibit mitotic and interphase cellular functions

Carbaglu

(carglumic acid)

Acute hyperammoniemia caused by N-acetylglutamate synthase deficiency/maintenance of chronic hyperammonemia due to NAGS deficiency

MOA: analoge of NAG, which activates CAS1 (first enzyme of the urea cycle which converts ammonia into urea)

Teflaro

(ceftaroline fosamil)

Xiaflex

(collagenase clostridium histolyticum)

Dupuytren's contracture in adults

MOA: a proteinase, hydrolzyes collagen resulting in lysis of collagen deposits

Pradaxa

(dabigatran etexilate)

Ampyra

(dalfampridine)

Improve walking in patients with MS

MOA: Broad spectrum K+ channel blocker, unknown how it exerts therapeutic effect

Prolia

(denosumab)

Postmenopausal women who have osteoporosis and a high risk for fracture

MOA: Receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor.

Xgeva

(denosumab)

Prevention of skeletal-related events in patients with bone metasteses from solid tumors

MOA: Receptor activator of nuclear factor kappa-B ligand (RANKL)

Halaven

(eribulin)

tx of metastatic breast cancer in pts who have undergone at least 2 tx cycles with an anthracycline and a taxane

MOA: a non-taxane microtubule inhibitor

Natazia

(estradiol valerate/estradiol velerate-dienogest)

Prevention of pregnancy

MOA: suppresses ovulation

TachoSil

(fibrin patch)

Prevention of mild/moderate bleeding from small blood vessels during CV surgery)

MOA: Thrombin and fibrinogen are on the patch. When in contact with physiologic fluids, the fibrinogen forms a fibrin clot and adheres the patch to the wound surface

Gilenya

(fingolimod)

tx of patients with relapsing MS

MOA: MOA unknown; may work by reducing the lymphocyte migration to the CNS

Cysview

(hexaminolevulinmate HCl)

Cytoscopic detection of non-muscle-invasive papillary bladder cancer in patients suspected/known to have the disease

MOA: Forms complexes in neoplastic cells. WHen excited with blue light, the complexes aid in detection of neoplastic lesions

Hizentra

(immune globulin, human)

treatment of primary humoral immunodeficiency

MOA: Many machinism in inflammatory/autoimmune disease

Xeomin

(incobotulinumtoxinA)

Treatmenmt of cervical dystonia or belpharospasm in adults

MOA: Blocks NM conduction by binding to receptor sites on motor nerve terminals, entering the nerve terminals, and inhibiting relase of ACh

Victoza

(liraglutide)

adjunct to diet/exercise to improve glycemic control in adults with T2DM

MOA: GLP-1 receptor agonsit that acts to increase insulin release in the presence of elevated glucose concentrations, decrease in glucagon secreion in a glucose-dependent manner, and delay gastric emptying

Latuda

(lurasidone HCl)

Schizophrenia

MOA: Acts as an antagonist at D2 and 5HT2A receptors

Menveo

(meningococcal - groups A, C, Y, and W-135)

Pancreaze

(Pancrelipase delayed release)

Tx of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions)

MOA: proteolytic, amylolytic, and lipolytic enzymes in pancrealipase enhance the digestion of proteins, startches, and fats in the duodenum and proximal small intestines

Krystexxa

(pegloticase)

Tx of chronic gout in adults who do not respond/cannot tolerate standard therapy in the disorder

MOA: PEGylated uric acid specific enzyme that lowers serum uric acid levels by catalyzing the oxidation of uric acid to allantoin (inert/water soluble purine metabolite that is readily eliminated by renal excretion)